Stock Traders Purchase Large Volume of Liquidia Call Options (NASDAQ:LQDA)

Liquidia Corporation (NASDAQ:LQDA) saw some unusual options trading activity on Friday. Investors bought 54,585 call options on the stock. This represents an increase of approximately 375% compared to the average volume of 11,501 call options.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Unusually large call-option activity: investors bought roughly 54,585 call options on Friday (about +375% vs. average call volume), which can indicate bullish bets or hedging by traders expecting upside in the near term.
• Positive Sentiment: Zacks upgraded LQDA from “hold” to “strong-buy,” a catalyst that can attract momentum-oriented investors and buy-side interest. Read More.
• Neutral Sentiment: Laughing Water Capital mentioned Liquidia in its Q4 2025 investor letter; the hedge fund reported modest positive returns for the quarter and year but the update does not directly signal a change in corporate fundamentals. Read More.
• Neutral Sentiment: Liquidia presented at the 44th Annual J.P. Morgan Healthcare Conference (transcript available); investor takeaways depend on specifics from the presentation (pipeline, commercial progress, guidance). Presentation transcripts tend to be informational until new data or guidance is revealed. Read More.
• Negative Sentiment: Multiple sizable insider sales were reported today across several filings — these include trades totaling roughly $507k, $768k, $493k and $791k (individual links below). Large, clustered insider selling can create near-term selling pressure and raise investor concern about insiders reducing exposure. Read More. Read More. Read More. Read More.
• Negative Sentiment: Additional insider transactions: the CAO sold shares worth ~$413k. Separate filing: director/executive Roger Jeffs sold 66,610 shares — both filings can be perceived negatively by the market. Read More. Read More.

Analysts Set New Price Targets

A number of equities analysts recently commented on LQDA shares. BTIG Research reiterated a “buy” rating and set a $49.00 price target on shares of Liquidia in a report on Friday, January 9th. Wall Street Zen lowered Liquidia from a “buy” rating to a “hold” rating in a report on Sunday. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a report on Wednesday, October 8th. Needham & Company LLC raised their price objective on shares of Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Finally, Wells Fargo & Company started coverage on shares of Liquidia in a research report on Monday, October 20th. They set an “overweight” rating and a $31.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.67.

Liquidia Trading Down 2.2%

Liquidia stock opened at $37.93 on Friday. Liquidia has a 1 year low of $11.26 and a 1 year high of $41.57. The firm’s 50 day moving average price is $32.91 and its 200-day moving average price is $26.04. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. The stock has a market cap of $3.30 billion, a P/E ratio of -26.34, a PEG ratio of 0.64 and a beta of 0.48.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The business had revenue of $54.34 million during the quarter, compared to analyst estimates of $18.86 million. The business’s revenue for the quarter was up 1106.7% compared to the same quarter last year. On average, equities analysts predict that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Activity at Liquidia

In other news, CFO Michael Kaseta sold 36,932 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,382,364.76. Following the sale, the chief financial officer owned 350,919 shares in the company, valued at approximately $13,134,898.17. This trade represents a 9.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jason Adair sold 13,548 shares of the stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $507,101.64. Following the sale, the insider owned 184,174 shares in the company, valued at approximately $6,893,632.82. This trade represents a 6.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 323,354 shares of company stock valued at $11,046,731. Company insiders own 26.50% of the company’s stock.

Institutional Trading of Liquidia

Institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Liquidia by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after acquiring an additional 1,700 shares during the period. Goldman Sachs Group Inc. lifted its position in Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after purchasing an additional 82,955 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Liquidia by 15.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after purchasing an additional 16,022 shares in the last quarter. Rhumbline Advisers grew its holdings in Liquidia by 6.0% during the 1st quarter. Rhumbline Advisers now owns 85,463 shares of the company’s stock valued at $1,261,000 after buying an additional 4,811 shares during the last quarter. Finally, Ballentine Partners LLC grew its stake in Liquidia by 10.2% in the 2nd quarter. Ballentine Partners LLC now owns 12,139 shares of the company’s stock worth $151,000 after acquiring an additional 1,119 shares during the period. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).